Your shopping cart is currently empty

SRI-31142 is a proposed brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies utilizing intracranial self-stimulation (ICSS), SRI-31142 does not produce the abuse-related effects observed with cocaine and GBR-12935. Instead, at effective doses, it reduces ICSS responding and dopamine levels in the nucleus accumbens (NAc). Additionally, SRI-31142 can prevent cocaine-induced increases in ICSS and NAc dopamine.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | SRI-31142 is a proposed brain-penetrant allosteric inhibitor of the dopamine transporter (DAT). In behavioral studies utilizing intracranial self-stimulation (ICSS), SRI-31142 does not produce the abuse-related effects observed with cocaine and GBR-12935. Instead, at effective doses, it reduces ICSS responding and dopamine levels in the nucleus accumbens (NAc). Additionally, SRI-31142 can prevent cocaine-induced increases in ICSS and NAc dopamine. |
| Molecular Weight | 456.54 |
| Formula | C29H24N6 |
| Cas No. | 1940118-04-6 |
| Smiles | N=1C=CC(=CC1)C(C=2C=CC=CC2)CNC3=NC(=NC=4C=CC=CC43)C5=CN6C=CN=C6C=C5C |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.